Revenue is effectively absent across most of the ten reported quarters, with the lone $20.0M 2026Q1 quarter producing a 100% gross margin that was overwhelmed by a -121.1% operating margin and -99.3% net margin, indicating the income statement reflects R&D-driven losses rather than any margin trajectory.
Rapport Therapeutics, Inc. Common Stock (RAPP) annual income statement — 4-year revenue, gross profit & net income history
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 |
|---|
| Sales/Revenue | 20M | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - |
| Cost of Goods Sold | 0 | 0 | 0 | 0 | 15K |
| COGS % of Revenue | - | - | - | - | - |
| Gross Profit | 20M | 0 | 0 | 0 | -15K |
| Gross Margin % | 100% | - | - | - | - |
| Gross Profit Growth % | - | - | - | 100% | - |
| Operating Expenses | 187.62M | 125.1M | 83.06M | 36.18M | 10.35M |
| OpEx % of Revenue | - | - | - | - | - |
| Selling, General & Admin | 38.91M | 30.31M | 22.12M | 8.18M | 1.37M |
| SG&A % of Revenue | - | - | - | - | - |
| Research & Development | 148.7M | 94.79M | 60.94M | 28M | 9.12M |
| R&D % of Revenue | - | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | -128.82K |
| Operating Income | -167.62M | -125.1M | -83.06M | -36.18M | -10.37M |
| Operating Margin % | -838.08% | - | - | - | - |
| Operating Income Growth % | - | -50.62% | -129.57% | -248.98% | - |
| EBITDA | -166.71M | -124.08M | -82.22M | -36.07M | -10.35M |
| EBITDA Margin % | -833.57% | - | - | - | - |
| EBITDA Growth % | -52.81% | -50.92% | -127.95% | -248.41% | - |
| D&A (Non-Cash Add-back) | 902K | 1.02M | 839K | 112K | 15K |
| EBIT | -159.57M | -125.1M | -83.06M | -34.78M | -10.37M |
| Net Interest Income | 17.15M | 13.62M | 12.14M | 2.53M | -285K |
| Interest Income | 17.15M | 13.62M | 12.14M | 2.53M | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 285K |
| Other Income/Expense | 17.15M | 13.62M | 4.75M | 1.4M | -285K |
| Pretax Income | -150.47M | -111.48M | -78.31M | -34.78M | -10.65M |
| Pretax Margin % | -752.35% | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 10K | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | -0.03% | 0% |
| Net Income | -150.47M | -111.48M | -78.31M | -34.79M | -10.65M |
| Net Margin % | -752.35% | - | - | - | - |
| Net Income Growth % | -54.01% | -42.37% | -125.11% | -226.57% | - |
| Net Income (Continuing) | -150.47M | -111.48M | -78.31M | -34.79M | -10.65M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -3.15 | -2.86 | -3.78 | -23.10 | -0.29 |
| EPS Growth % | -16.97% | 24.34% | 83.64% | -7865.52% | - |
| EPS (Basic) | - | -2.86 | -3.78 | -23.10 | -0.29 |
| Diluted Shares Outstanding | 47.77M | 38.93M | 20.74M | 1.51M | 20.12M |
| Basic Shares Outstanding | 47.77M | 38.93M | 20.74M | 1.51M | 20.12M |
| Dividend Payout Ratio | - | - | - | - | - |
Quick answers to the most common questions about buying RAPP stock.
For fiscal year 2025, Rapport Therapeutics, Inc. Common Stock (RAPP) reported total revenue of $0.0M.
Rapport Therapeutics, Inc. Common Stock (RAPP) reported a net loss of $111.5M for the fiscal year ending 2025.
Key Metrics
Top Statement Risk
Pivotal trial funding dependence
Metrics are mathematically derived from official filings.
Revenue Absent, Losses Scaling With R&D
Based on the reported quarterly income statement, RAPP recorded no product revenue across most of the ten quarters, with a single $20.0M quarter in 2026Q1 that appears non-recurring and does not establish a growth trend.
The reported figures suggest the company remains a pre-revenue clinical-stage business, so conventional growth rates are not meaningful here. The lone revenue quarter likely reflects a collaboration or milestone-type receipt rather than durable sales, which warrants further investigation before it is treated as a base for projection. Investors should monitor whether future quarters show recurring receipts, since the cost base is expanding independently of any top-line build.
Operating Losses Widening Faster Than Overhead
Reported R&D expense rose from roughly $15.5M in 2024Q3 to $51.4M in 2026Q2, while SG&A stayed comparatively contained near $6M to $11M, indicating operating losses are driven almost entirely by clinical spend.
The divergence between R&D growth and SG&A stability suggests that the cost base is tied to trial execution rather than to a scalable commercial infrastructure. Operating losses that grew from about $21.6M to over $60M imply negative operating leverage in the near term, since no revenue offsets the expanding spend. This pattern appears consistent with a company prioritizing pivotal-stage development over overhead efficiency.
Net Losses Reflect Burn, Not Accounting Noise
Net losses track operating losses closely, and reported stock-based compensation of $7.6M in 2026Q3 and $7.2M in 2026Q2 represents a non-cash drag that is modest relative to the roughly $40M to $57M net losses in those quarters.
Because net income is essentially operating loss with minimal non-operating offset, the headline loss is a fair reflection of cash-consuming activity rather than an accounting distortion. Stock-based compensation is material but not dominant, so adjusting for it would narrow the loss only modestly. The quarterly EPS swings, such as -0.42 in 2026Q1 against -1.19 in 2026Q2, appear driven by share count dynamics and lumpy trial costs rather than by changes in underlying earnings quality.
R&D Dominates a Lean Overhead Structure
According to reported financials, R&D accounted for the large majority of total operating expense in recent quarters, with 2026Q2 R&D of $51.4M against SG&A of $9.4M, implying roughly 85 percent of spend tied to clinical programs.
The cost structure is clearly concentrated in development, which fits a company advancing RAP-219 through pivotal-stage work. SG&A has remained within a narrow band, suggesting management is holding administrative expansion in check while trial spend scales. Investors should watch whether R&D continues to rise into pivotal readouts, since that trajectory determines how quickly the company will need additional capital.
Burn Rate Outpaces Visible Funding Support
The strongest challenge is that quarterly operating losses above $40M, with no offsetting revenue, may outpace the disclosed $52.6M cash figure, which suggests equity dilution is a plausible near-term path rather than a remote risk.
If the reported $52.6M cash position is accurate and recent quarterly losses approach $40M to $60M, the visible runway appears short relative to pivotal trial timelines. This analytical inference points to a financing event, but the available data does not confirm current liquidity, so the conclusion warrants further investigation against the latest balance sheet. Binary sensitivity to trial readouts is elevated, and a financing that occurs before data could compress valuation.